Aklief Shortage: What Providers and Prescribers Need to Know in 2026

As a prescriber, you've likely heard from patients who can't find Aklief (Trifarotene) at their pharmacy. While Aklief isn't in a formal FDA-listed shortage, the practical reality is that many patients face significant barriers to filling this prescription. This briefing covers the current supply landscape, cost considerations, and actionable strategies to help your patients access this medication.

Current Supply Status: Not a Shortage, But Not Simple

As of March 2026, Aklief is not listed on the FDA's drug shortage database. Galderma Laboratories continues to manufacture and distribute Aklief Cream 0.005% (Trifarotene) in 45g airless pump bottles without interruption.

The availability challenge is driven by pharmacy stocking decisions, not manufacturing constraints. Key factors include:

• High acquisition cost: Wholesale acquisition cost makes Aklief an expensive inventory item for pharmacies
• Limited insurance coverage: Many commercial and most Medicare plans don't cover Aklief, reducing prescription volume
• Brand-name exclusivity: No generic Trifarotene exists; patents extend through 2031 to 2033
• Low formulary placement: Plans that do cover Aklief often place it on specialty or non-preferred tiers

Timeline and Background

Aklief received FDA approval on October 4, 2019, making it the first new retinoid molecule approved for acne in over 20 years. Trifarotene is a fourth-generation retinoid that selectively targets retinoic acid receptor gamma (RAR-γ), the predominant retinoid receptor in human skin.

Key regulatory milestones:

• October 2019: FDA approval for acne vulgaris in patients ≥9 years
• October 2024: New Chemical Entity (NCE) exclusivity expired
• 2031-2033: Patent protection expected to end

Despite NCE exclusivity expiring in 2024, no generic manufacturers have filed abbreviated new drug applications (ANDAs) for Trifarotene as of this writing, likely due to the complexity of the cream formulation and remaining patent protections.

Prescribing Implications

When prescribing Aklief, providers should be aware of several practical considerations:

Prior Authorization Requirements

Many insurance plans require prior authorization for Aklief. Common criteria include:

• Documented failure of at least one first-line topical retinoid (Tretinoin or Adapalene)
• Diagnosis of acne vulgaris (ICD-10: L70.0)
• Patient age ≥9 years
• Prescription written by or in consultation with a dermatologist (some plans)

Step Therapy Protocols

Step therapy requirements typically mandate trials of:

1. Generic Tretinoin (cream or gel, various strengths)
2. Adapalene 0.1% or 0.3%
3. Combination products (e.g., Adapalene/Benzoyl Peroxide)

Document therapeutic failures and adverse reactions thoroughly to support prior authorization appeals.

Patient Counseling Points

• Apply a thin layer once daily in the evening to clean, dry skin
• Use a moisturizer from the initiation of treatment
• Expect initial irritation (erythema, scaling, dryness) — this typically improves over 2 to 4 weeks
• Minimize sun exposure; use broad-spectrum sunscreen daily
• Avoid application to cuts, abrasions, eczematous, or sunburned skin
• Avoid waxing on treated areas

For detailed side effect information to share with patients, see Aklief side effects: what to expect.

Availability Picture

The pharmacy availability landscape for Aklief can be summarized as follows:

• Large chain pharmacies (CVS, Walgreens, Rite Aid): Inconsistent stocking; many locations can order within 1 to 3 business days but don't keep it on shelf
• Independent pharmacies: Variable; those near dermatology practices are more likely to stock it
• Mail-order pharmacies: Generally available but may require prior authorization verification
• Specialty pharmacies: Most reliable stocking but may not be convenient for patients

Providers can direct patients to Medfinder for Providers to check real-time pharmacy availability in their area.

Cost and Access Considerations

Pricing Overview

• Average retail price: $760 to $1,080 for 45g pump
• GoodRx/SingleCare coupon price: ~$670 to $760
• Galderma CareConnect (commercially insured): As low as $20
• Galderma CareConnect (cash-paying): No more than $90

Galderma CareConnect Program Details

The manufacturer savings program is the most impactful cost-reduction tool for Aklief:

• Available to commercially insured and cash-paying patients
• Not available to patients with government-sponsored insurance (Medicare, Medicaid, Tricare, VA)
• Valid for up to 15 uses per calendar year
• Patients can enroll at aklief.com/savings or call 855-280-0543
• Card can be presented at any participating pharmacy

For Medicare and Medicaid patients, no formal patient assistance program (PAP) is currently available from Galderma. These patients may benefit from referral to NeedyMeds.org or RxAssist.org for additional support resources.

For a comprehensive savings guide to share with patients, see how to save money on Aklief.

Tools and Resources for Your Practice

Medfinder for Providers

Medfinder offers a provider-facing tool that helps practices:

• Check real-time pharmacy availability for Aklief
• Direct patients to specific pharmacies with stock
• Reduce callback volume from patients struggling to fill prescriptions

Sample Programs

Contact your Galderma representative about sample availability. Providing an initial pump of Aklief allows patients to begin treatment immediately while navigating pharmacy and insurance logistics.

Prior Authorization Support

Galderma offers prior authorization support through their medical affairs team. Contact information is available through the Aklief HCP website or your local Galderma representative.

Alternative Agents to Consider

When Aklief is not accessible or appropriate, consider these topical retinoid alternatives:

• Tretinoin (generic): First-line, widely available, $15 to $50 cash price; multiple strengths and formulations
• Adapalene 0.3% (Differin): Better tolerated than Tretinoin; available as generic prescription; OTC at 0.1%
• Tazarotene (Tazorac, Arazlo): Most potent topical retinoid; Arazlo lotion may be better tolerated; brand-name only ($400 to $700)

For a patient-facing comparison, direct patients to alternatives to Aklief.

Looking Ahead

Several developments may improve Aklief access in the coming years:

• Generic entry: The earliest patents expire in 2031, which could open the door for generic Trifarotene — though formulation complexity may delay generic availability
• Expanded insurance coverage: As clinical evidence for Aklief's unique benefits (particularly for truncal acne) accumulates, formulary committees may expand coverage
• Additional indications: Research into Trifarotene for other dermatologic conditions could broaden the patient population and increase pharmacy stocking

Final Thoughts

Aklief represents a meaningful advancement in topical retinoid therapy, particularly for patients with truncal acne. While access barriers exist, providers can play a critical role in helping patients navigate cost and availability challenges. Leveraging tools like Medfinder, the Galderma CareConnect savings program, and proactive prior authorization support can make the difference between a patient who gives up and one who gets treated.

For additional provider resources, see our guide on how to help your patients find Aklief in stock.